{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:33:23Z","timestamp":1780961603859,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4ts-Herzzentrum Freiburg - Bad Krozingen GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>This study aimed to assess the association between myocardial infarction (MI) size and clinical outcome with ongoing Sodium-glucose-cotransporter-2 inhibitor (SGLT2-i) use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and results<\/jats:title>\n            <jats:p>In this retrospective single-center cohort study 681 patients with MI and diabetes mellitus type 2 (T2DM) treated with percutaneous coronary intervention (PCI) between November 2015 and December 2023 were included. 105 patients received ongoing SGLT2-i therapy and 576 were taking other glucose-lowering medication at the time of admission. The primary outcome was the size of MI. MI size was determined by the peak high-sensitive troponinT (hs-TnT x ULN [upper limit of normal]) normalized on the endangered myocardial area (EMA). No significant statistical differences were observed in hs-TnT values (hsTnT x ULN: 55 [13\u2013174] vs. 68 [22\u2013182]; <jats:italic>p<\/jats:italic>\u2009=\u20090.36) and EMA (41 [29\u201359] vs. 35 [24\u201359] %; <jats:italic>p<\/jats:italic>\u2009=\u20090.24) between patients with and without SGLT2-i therapy. After augmented inverse-probability weighted analyses, ongoing SGLT2-i therapy was not significantly associated with a reduced MI size (difference between means hsTnT x ULN\/EMA [1\/%]: \u2212\u20090.24 [95% confidence interval, \u2212\u20092.95 to 2.48]; <jats:italic>p<\/jats:italic>\u2009=\u20090.54). Secondary outcomes were in-hospital major adverse events and length of intensive care unit (ICU) treatment. SGLT2-i use was not associated with fewer in-hospital adverse events (3.81, vs. 4.17% [95% CI, \u2212\u20092.95 to 2.48], <jats:italic>p<\/jats:italic>\u2009=\u20090.94) or with fewer days on ICU (1 [1\u20131] vs. 1 [1\u20132] days, <jats:italic>p<\/jats:italic>\u2009=\u20090.78).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In this retrospective cohort study of T2DM patients presenting with MI, prior prescription of SGLT2-i was not associated with reduced MI size or fewer adverse events during hospitalization for MI treated with PCI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration number and date<\/jats:title>\n            <jats:p>DRKS00032432 (Registration Date: 07 August 2023).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12872-025-04981-5","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:27:37Z","timestamp":1754108857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2-inhibition and myocardial infarction size in patients with type 2 diabetes mellitus\u2013 Insights from an acute cardiovascular care center"],"prefix":"10.1186","volume":"25","author":[{"given":"Istvan","family":"Bojti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Bojti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tau","family":"Hartikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Breibart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"L\u00f6ffelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Valina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph B.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"4981_CR1","first-page":"e84353","volume":"17","author":"S Rabizadeh","year":"2019","unstructured":"Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and renal benefits of SGLT2 inhibitors: A narrative review. Int J Endocrinol Metab. 2019;17:e84353.","journal-title":"Int J Endocrinol Metab"},{"key":"4981_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose Co-Transporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci. 2020;5:632\u201344.","journal-title":"JACC Basic Transl Sci"},{"key":"4981_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"4981_CR4","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","volume":"43","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43:4421\u201332.","journal-title":"Eur Heart J"},{"key":"4981_CR5","doi-asserted-by":"publisher","first-page":"e027824","DOI":"10.1161\/JAHA.122.027824","volume":"12","author":"O Kwon","year":"2023","unstructured":"Kwon O, et al. Sodium-Glucose Cotransporter\u20102 inhibitors after acute myocardial infarction in patients with type 2 diabetes: A Population\u2010Based investigation. J Am Heart Association. 2023;12:e027824.","journal-title":"J Am Heart Association"},{"key":"4981_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"Butler","year":"2024","unstructured":"Butler, Javed, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390:1455\u201366.","journal-title":"N Engl J Med"},{"key":"4981_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James S, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3:EVIDoa2300286.","journal-title":"NEJM Evid"},{"key":"4981_CR8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/eurheartj\/ehm213","volume":"28","author":"BL Gerber","year":"2007","unstructured":"Gerber BL. Risk area, infarct size, and the exposure of the wavefront phenomenon of myocardial necrosis in humans. Eur Heart J. 2007;28:1670\u20132.","journal-title":"Eur Heart J"},{"key":"4981_CR9","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","volume":"67","author":"GW Stone","year":"2016","unstructured":"Stone GW, et al. Relationship between infarct size and outcomes following primary PCI. J Am Coll Cardiol. 2016;67:1674\u201383.","journal-title":"J Am Coll Cardiol"},{"key":"4981_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000337113","volume":"121","author":"J Hall\u00e9n","year":"2012","unstructured":"Hall\u00e9n J. Troponin for the Estimation of infarct size: what have we learned?? Cardiology. 2012;121:204\u201312.","journal-title":"Cardiology"},{"key":"4981_CR11","first-page":"15","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim VG, et al. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC: Basic Translational Sci. 2019;4:15\u201326.","journal-title":"JACC: Basic Translational Sci"},{"key":"4981_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00125-020-05359-2","volume":"64","author":"AA Sayour","year":"2021","unstructured":"Sayour AA, et al. Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis. Diabetologia. 2021;64:737\u201348.","journal-title":"Diabetologia"},{"key":"4981_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","volume":"21","author":"P Paolisso","year":"2022","unstructured":"Paolisso P, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21:77.","journal-title":"Cardiovasc Diabetol"},{"key":"4981_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237\u201369.","journal-title":"Eur Heart J"},{"key":"4981_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"F-J Neumann","year":"2019","unstructured":"Neumann F-J, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"4981_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.acvd.2018.12.001","volume":"112","author":"M Schaaf","year":"2019","unstructured":"Schaaf M, et al. Which high-sensitivity troponin variable best characterizes infarct size and microvascular obstruction? Arch Cardiovasc Dis. 2019;112:334\u201342.","journal-title":"Arch Cardiovasc Dis"},{"key":"4981_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.compmedimag.2007.06.008","volume":"31","author":"Z Koszegi","year":"2007","unstructured":"Koszegi Z, et al. Holistic Polar map for integrated evaluation of cardiac imaging results. Comput Med Imaging Graph. 2007;31:577\u201386.","journal-title":"Comput Med Imaging Graph"},{"key":"4981_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1161\/hc0402.102975","volume":"105","author":"M Cerqueira","year":"2002","unstructured":"Cerqueira M, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. Circulation. 2002;105:539\u201342.","journal-title":"Circulation"},{"key":"4981_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0002-9149(67)90023-9","volume":"20","author":"T Killip","year":"1967","unstructured":"Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: A two year experience with 250 patients. Am J Cardiol. 1967;20:457\u201364.","journal-title":"Am J Cardiol"},{"key":"4981_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/biomet\/90.1.15","volume":"90","author":"PK Andersen","year":"2003","unstructured":"Andersen PK, Klein JP, Rosth\u00f8j S. Generalised linear models for correlated pseudo-observations, with applications to multi\u2010state models. Biometrika. 2003;90:15\u201327.","journal-title":"Biometrika"},{"key":"4981_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jacc.2007.09.041","volume":"51","author":"E Giannitsis","year":"2008","unstructured":"Giannitsis E, et al. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single Time-Point measurements of cardiac troponin T. J Am Coll Cardiol. 2008;51:307\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"4981_CR22","first-page":"775","volume":"5","author":"NI Parikh","year":"2012","unstructured":"Parikh NI, et al. Left and codominant coronary artery circulations are associated with higher In-Hospital mortality among patients undergoing percutaneous coronary intervention for acute coronary syndromes. Circulation: Cardiovasc Qual Outcomes. 2012;5:775\u201382.","journal-title":"Circulation: Cardiovasc Qual Outcomes"},{"key":"4981_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12872-019-1007-5","volume":"19","author":"L Wang","year":"2019","unstructured":"Wang L, et al. Association between coronary dominance and acute inferior myocardial infarction: a matched, case-control study. BMC Cardiovasc Disord. 2019;19:35.","journal-title":"BMC Cardiovasc Disord"},{"key":"4981_CR24","doi-asserted-by":"publisher","first-page":"e004376","DOI":"10.1161\/CIRCIMAGING.115.004376","volume":"9","author":"D Nordlund","year":"2016","unstructured":"Nordlund D, et al. Extent of myocardium at risk for left anterior descending artery, right coronary artery, and left circumflex artery occlusion depicted by Contrast-Enhanced steady state free precession and T2-Weighted short Tau inversion recovery magnetic resonance imaging. Circ Cardiovasc Imaging. 2016;9:e004376.","journal-title":"Circ Cardiovasc Imaging"},{"key":"4981_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00392-008-0735-9","volume":"98","author":"J Kammler","year":"2009","unstructured":"Kammler J, et al. TIMI 3 flow after primary angioplasty is an important predictor for outcome in patients with acute myocardial infarction. Clin Res Cardiol. 2009;98:165\u201370.","journal-title":"Clin Res Cardiol"},{"key":"4981_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacc.2008.05.009","volume":"52","author":"G Ndrepepa","year":"2008","unstructured":"Ndrepepa G, et al. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;52:512\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"4981_CR27","doi-asserted-by":"publisher","first-page":"e029670","DOI":"10.1161\/JAHA.123.029670","volume":"12","author":"C Wu","year":"2023","unstructured":"Wu C, et al. Role of ST-Segment resolution alone and in combination with TIMI flow after primary percutaneous coronary intervention for ST\u2010Segment\u2013Elevation myocardial infarction. J Am Heart Association. 2023;12:e029670.","journal-title":"J Am Heart Association"},{"key":"4981_CR28","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/jpm13081217","volume":"13","author":"N Maruszak","year":"2023","unstructured":"Maruszak N, et al. Risk factors of suboptimal coronary blood flow after a percutaneous coronary intervention in patients with acute anterior wall myocardial infarction. J Personalized Med. 2023;13:1217.","journal-title":"J Personalized Med"},{"key":"4981_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12872-020-01673-0","volume":"20","author":"K Elakabawi","year":"2020","unstructured":"Elakabawi K, et al. Predictors of suboptimal coronary blood flow after primary angioplasty and its implications on short-term outcomes in patients with acute anterior STEMI. BMC Cardiovasc Disord. 2020;20:391.","journal-title":"BMC Cardiovasc Disord"},{"key":"4981_CR30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jacc.2016.05.049","volume":"68","author":"RL McNamara","year":"2016","unstructured":"McNamara RL, et al. Predicting In-Hospital mortality in patients with acute myocardial infarction. J Am Coll Cardiol. 2016;68:626\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"4981_CR31","doi-asserted-by":"publisher","first-page":"110766","DOI":"10.1016\/j.diabres.2023.110766","volume":"202","author":"P Paolisso","year":"2023","unstructured":"Paolisso P, et al. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry. Diabetes Res Clin Pract. 2023;202:110766.","journal-title":"Diabetes Res Clin Pract"},{"key":"4981_CR32","doi-asserted-by":"publisher","first-page":"768214","DOI":"10.3389\/fcvm.2021.768214","volume":"8","author":"Y-W Yu","year":"2021","unstructured":"Yu Y-W, et al. Sodium-Glucose Co-transporter-2 inhibitor of Dapagliflozin attenuates myocardial ischemia\/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy. Front Cardiovasc Med. 2021;8:768214.","journal-title":"Front Cardiovasc Med"},{"key":"4981_CR33","first-page":"e006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (Nucleotide-Binding Domain-Like receptor protein 3) inflammasome activation in heart failure. Circulation: Heart Fail. 2020;13:e006277.","journal-title":"Circulation: Heart Fail"},{"key":"4981_CR34","doi-asserted-by":"publisher","first-page":"1012220","DOI":"10.3389\/fcvm.2022.1012220","volume":"9","author":"A Cesaro","year":"2022","unstructured":"Cesaro A, et al. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med. 2022;9:1012220.","journal-title":"Front Cardiovasc Med"},{"key":"4981_CR35","doi-asserted-by":"publisher","first-page":"41530","DOI":"10.1038\/srep41530","volume":"7","author":"R-I Mincu","year":"2017","unstructured":"Mincu R-I, J\u00e1nosi RA, Vinereanu D, Rassaf T, Totzeck M. Preprocedural C-Reactive protein predicts outcomes after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction a systematic meta-analysis. Sci Rep. 2017;7:41530.","journal-title":"Sci Rep"},{"key":"4981_CR36","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.3390\/jcm8111814","volume":"8","author":"F Iannantuoni","year":"2019","unstructured":"Iannantuoni F, et al. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med. 2019;8:1814.","journal-title":"J Clin Med"},{"key":"4981_CR37","doi-asserted-by":"publisher","unstructured":"Mustapic I, Bakovic D, Susilovic-Grabovac Z, Borovac JA. Left ventricular systolic function after 3 months of SGLT2 inhibitor therapy in heart failure patients with reduced ejection fraction. J Cardiovasc Transl Res. 2023;1\u201312. https:\/\/doi.org\/10.1007\/s12265-023-10389-3.","DOI":"10.1007\/s12265-023-10389-3"},{"key":"4981_CR38","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2023;44:3627\u201339.","journal-title":"Eur Heart J."},{"key":"4981_CR39","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1161\/01.CIR.0000027818.15792.1E","volume":"106","author":"BL Gerber","year":"2002","unstructured":"Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JAC. Accuracy of Contrast-Enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation. 2002;106:1083\u20139.","journal-title":"Circulation"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04981-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:39:55Z","timestamp":1757331595000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04981-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4981"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04981-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and amendments were approved by the local ethics committee, privacy and security offices, and institutional review board (Ethik-Kommission Albert-Ludwigs-Universit\u00e4t Freiburg, 21-1667). The need for consent to participate was waived by the institutional review board. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IB: speakers fee from Novartis, FB: none, TH: Travel Grants from Boston Scientific and Novartis, NL: speakers fee from BMS and Daiichi Sankyo, PB: consultant and speakers fee from AstraZeneca and Boehringer Ingelheim, DW: Honorary from Abiomed, Astra Zeneca, Bayer, B\u00f6hringer Ingelheim, Medtronic, Novartis, CV: none, DeW: research support from European Research Council, Deutsche Forschungsgemeinschaft, Else Kr\u00f6ner-Fresenius Stiftung. Honoraria: Novo Nordisc, Bayer, Novartis, UCB, B\u00f6hringer Ingelheim, CBO: research support from Haemonetics, Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, Else Kr\u00f6ner-Fresenius Stiftung Faculty of Medicine - Freiburg University; honoraria: Bayer Vital GmbH, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ferrer, Johnson & Johnson.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"566"}}